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1 Abbreviations  
 
AraR Arabinose repressor 
CBS Cystathionine beta synthase domain 
CcpA Catabolite control protein A 
CcpN Catabolite control protein N 
CD Cluster of differentiation 
CD44 Hyaluronate receptor 
CD44s Standard isoform of CD44 
CD44v Variant isoform of CD44 
C-DeoR C-terminal effector-binding domain of deoxyribonucleoside 
CggR Central glycolytic genes regulator 
c-myc Transcription factor, proto-oncogene 
CP Cytoplasmic region 
cre Catabolite-responsive element 
CrH Catabolite repression Hpr-like protein 
DBD DNA-binding bomain 
DBTBS Database of transcriptional regulation in B. subtilis 
deo Deoxyribonucleoside catabolism operon from E. coli 
DeoR Deoxyribonucleoside regulator 
Dra Deoxyriboaldolase 
Drm Phosphodeoxyribomutase 
EBD Effector-binding domain 
EGF Epidermal growth factor 
ERM Ezrin, radixin, moesin 
FadR Fatty acid metabolism regulator 
FrlR Fructosamine repressor 
FruR Fructose repressor 
GamR Glucosamine repressor 
glp Glycerolphosphate operon 
GmuR Glucomannan operon repressor 
GntR Gluconate operon repressor 
HABD Hyaluronate-binding domain 
HER2 Human epidermal growth factor receptor 2 
HPr Phosphocarrier protein 
HSQC Heteronuclear single quantum coherence 
HutC Histidine utilization repressor 
Ig Immunoglobulin 
IolR Myo-inositol operon repressor 
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LacI Lactose operon repressor 
MALDI-TOF Matrix-assisted laser desorption/ionization, time of flight 
MEM-57 Murine monoclonal antibody against human CD3 
MEM-85 Murine monoclonal antibody against human CD44 
Mfd Mutation frequency decline (transcription repair coupling factor) 
NagC N-acetylglucosamine repressor 
NagR N-acetylglucosamine repressor 
NMR Nuclear magnetic resonance 
NupC Nucleoside uptake protein C 
O Ordered conformation 
PD Partially disordered conformation 
PDB Protein Data Bank (http://www.rcsb.org) 
Pdp Pyrimidine nucleoside phosphorylase 
pelB Pectate lyase B leader sequence 
PRD Phosphotransferase regulator domain 
PTS Phosphoenolpyruvate: sugar phosphotransferase system 
RAT Ribonucleic antiterminator sequence 
RbsR Ribose operon repressor 
SAXS Small-angle X-ray scattering 
scFv Single-chain variable antibody fragment 
siRNA Small interfering RNA 
SorC Sorbitol operon regulator 
SPR Surface plasmon resonance 
TCR T-cell receptor 
TM Transmembrane region 
Tm Melting temperature 
TreR Trehalose repressor 
VH Variable domain of the antibody heavy chain 
VL Variable domain of the antibody light chain 
XylR Xylose operon repressor 
YbgA Alternative name for GamR 
YdhQ Alternative name for GmuR 
YvoA Alternative name for NagR 
σA RNA polymerase σ-43 factor  




Understanding protein function highly benefits from the knowledge of its 
three-dimensional structure, especially in the case of protein-ligand complexes. Structural 
biology methods such as X-ray crystallography, SAXS and NMR are therefore widely used 
for structural studies of protein-ligand interaction. In this work, these methods were used to 
understand two biological processes involving protein interactions: X-ray structural 
analysis was used to study binding of effector molecule to a prokaryotic transcription 
factor. NMR and SAXS techniques were used to study interacion of a monoclonal 
antibody with its protein antigen.  
Transcriptional regulator DeoR negatively regulates the expression of catabolic genes 
for the utilization of deoxyribonucleosides and deoxyribose in Bacillus subtilis. DeoR 
comprises an N-terminal DNA-binding domain and a C-terminal effector-binding domain 
(C-DeoR), and its function is regulated by binding of a small-molecular effector 
deoxyribose-5-phosphate. We determined crystal structu es of C-DeoR both in the free 
form and in complex with deoxyribose-5-phosphate. Structural analysis revealed unique 
covalent binding of effector molecule through a reversible Schiff-base double bond with an 
effector-binding-site lysine residue. The physiological nature of this binding mode was 
confirmed by mutational analysis and mass spectrometry of the Schiff-base adducts formed 
in solution. Comparison of the free and effector-bound structures of C-DeoR explained on 
a molecular level the mechanism of DeoR function as a molecular switch.  
CD44, the cell receptor for hyaluronate, is involved in cell adhesion, migration, and 
tumor metastasis. CD44 binds hyaluronate through the hyaluronate-binding domain 
(HABD), which triggers an extensive conformational rearrangement in HABD that induces 
CD44 shedding. We constructed a single-chain variable fragment (scFv) of antibody 
MEM-85. MEM-85 is of therapeutic interest, recognizes a poorly characterized epitope in 
HABD, blocks hyaluronate binding, and induces CD44 shedding. Antibody scFv 
fragments exhibit poor homogeneity caused by scFv oligomerization. We developed 
a novel optimization approach, which we used for the preparation of a homogeneous scFv 
sample for NMR-based mapping of the epitope of MEM-85 in HABD. This mapping 
together with mutational analysis identified epitope residues in the C-terminal tail of the 
HABD. Additionally, we built a rigid-body model of the HABD – scFv MEM-85 complex 
based on the SAXS data. These biophysical methods provided a detailed insight into the 
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mechanism of MEM-85 action: MEM-85 binds to an epito e located outside the 
hyaluronate-binding site and induces a conformationl change in the HABD tail, similar to 
that induced by hyaluronate. The mechanism of MEM-85 cross-blocking of hyaluronate 
binding is not a direct physical competition, but rather an allosteric, relay-like effect. 
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3 Abstrakt  
 
K pochopení funkce proteinu významně přispívá znalost jeho trojrozměrné struktury, 
obzvláště v případě komplexů s ligandy. Metody strukturní biologie, jako je rentgenová 
krystalografie, SAXS nebo NMR, jsou proto ve strukturní analyse interakcí proteinů 
s ligandy široce využívány. V této práci byly tyto metody využity k objasnění molekulární 
podstaty dvou biologických dějů využívajících proteinové interakce: rentgenostrukturní 
analysa byla použita ke studiu vazby efektorové molekuly k prokaryotnímu transkripčnímu 
faktoru, metody NMR a SAXS byly využity ke studiu interakce monoklonální protilátky 
s proteinovým antigenem.  
Transkripční regulátor DeoR negativně reguluje expresi katabolických genů pro 
utilizaci deoxyribonukleosidů a deoxyribosy v bakterii Bacillus subtilis. DeoR se skládá 
z N-koncové DNA-vazebné domény a z C-koncové efektor-vazebné domény (C-DeoR). 
Jeho funkce je regulována vazbou nízkomolekulárního efektoru deoxyribosa-5-fosfátu. 
Vyřešili jsme krystalové struktury C-DeoR ve volné formě a v komplexu 
s deoxyribosa-5-fosfátem. Strukturní analysa odhalila unikátní vazbu mezi molekulou 
efektoru a lysylovým zbytkem efektor-vazebného místa prostřednictvím reversibilní 
dvojné vazby typu Schiffovy base. Fysiologická relevance této vazby byla potvrzena 
mutačními experimenty a také analysou tvorby kovalentních aduktů v roztoku pomocí 
hmotnostní spektrometrie. Porovnání struktur volné C-DeoR a komplexu C-DeoR 
s efektorem vysvětlilo na molekulární úrovni funkci DeoR jako molekulárního spínače.  
CD44, buněčný receptor pro hyaluronát, se účastní buněčné adhese, migrace 
a metastazování nádorů. CD44 váže hyaluronát prostřednictvím hyaluronát-vazebné 
domény (HABD), což indukuje v HABD rozsáhlou konformační změnu, vedoucí 
k proteolytickému uvolnění CD44 z povrchu buněk. Vytvořili jsme jednořetězcový 
variabilní fragment (scFv) protilátky MEM-85. MEM-85 má terapeutický potenciál, 
rozpoznává nedostatečně popsaný epitop v HABD, blokuje vazbu hyaluronátu a indukuje 
odštěpení CD44. Fragmenty scFv jsou kvůli své oligomeraci obvykle nehomogenní. 
Vyvinuli jsme nový optimalizační přístup, pomocí něhož jsme připravili homogenní 
vzorek scFv vhodný pro NMR mapování antigen-vazebného epitopu protilátky MEM-85 
v CD44 HABD. Toto mapování společně s mutační analysou vedlo k identifikaci 
protilátkového epitopu v C-koncové části HABD. Na základě SAXS analysy jsme také 
vytvořili model komplexu HABD s scFv MEM-85. Tyto biofysikální metody přinesly 
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detailní vhled do mechanismu funkce MEM-85: MEM-85 váže epitop, který se nachází 
mimo hyaluronát-vazebné místo, a indukuje v C-konci HABD strukturní změny, jež jsou 
podobné změnám vyvolaným vazbou hyaluronátu. Blokace vazby hyaluronátu protilátkou 
MEM-85 proto nespočívá ve fysické kompetici o vazebné místo, ale jde spíše 





This work includes a combination of two research projects: structural studies of 
prokaryotic transcriptional regulators and structural studies of antibody-antigen interaction. 
The common basis of both projects is the understanding of protein-protein and 
proteinligand interactions and their effects on protein structure and function through 
structural biology. The first project is based on protein X-ray crystallography technique, 
whereas the second one utilizes NMR and SAXS techniques, illustrating thus the powerful 
synergy of these methods in structural biology.  
 
X-ray crystallography is the principal method for determination of structures of 
biological macromolecules. It has made an immense impact in the field of biochemical and 
biological research; there have been 25 Nobel laureates connected to X-ray 
crystallography. Determination of protein three-dimensional structure is driven by the 
objective to gain the knowledge on the protein’s biological activity, which is very often 
associated with the characterization of ligand binding. In an ideal case, X-ray 
crystallography enables structure determination for protein-protein and protein-ligand 
complexes at a resolution high enough to directly observe atomic details of covalent and 
non-covalent interactions in three dimensions. This allows for further analysis of the 
protein’s mode of action on the molecular level, as well as for the design of 
small-molecular inhibitors of the protein’s function. Moreover, the knowledge of 
high-resolution three-dimensional structures of the protein in the free and ligand-bound 
states constitutes the basis for understanding the ligand-induced changes in the protein 
conformation and thus unravels the effects of the ligand binding on the function of the 
protein.  
The use of X-ray crystallography is irreplaceable for the detailed studies of the function 
of prokaryotic transcriptional regulators on the molecular level. These transcription factors 
function as molecular switches and their action usually includes extensive ligand-induced 
conformational changes associated with the modulation of oligomeric state. The first part 
of this thesis comprises X-ray structural study of deoxyribonucleoside regulator DeoR 
from Bacillus subtilis with the aim to undestand the regulation of its function by the 
small-molecular effector, deoxyribose-5-phosphate.  
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NMR methods play a prominent role in biochemistry and molecular biophysics for 
probing molecular structure and interactions. X-ray cr stallography is still a simpler and 
more straightforward method of structure determinatio , especially in the case of larger 
molecules and complexes. However, solution NMR is the method of choice in structure 
determination of molecules that are resistive to forming well-ordered crystals. Moreover, 
the classical NMR applications, where the complete structure determination is not the goal, 
demonstrate the wide-range impact of NMR in biological and biophysical research. In 
particular, solution NMR has become the paramount me hod for studying molecular 
dynamics and for characterization of protein-ligand and protein-protein interactions. The 
method of choice for this application is the differential chemical shift perturbation method, 
which is based on the fact that the NMR-active nuclei that are located at the interaction 
interface undergo changes in their chemical shift, which are not observed for distant nuclei. 
Therefore, the location of the binding site on the protein can be mapped.  
Recently, this widely applicable approach has been increasingly used to characterize 
antigen – antibody complexes, usually for the definitio  of the antigen-binding epitopes of 
therapeutic antibody fragments. The second part of this thesis is focused on the 
characterization of antibody binding to a cancer marker CD44. We have prepared 
a single-chain variable fragment of antibody MEM-85, which recognizes human CD44 
antigen and which is of therapeutic potential and employed the NMR-based differential 





5.1 Regulation of metabolism in Bacillus subtilis 
In order to be evolutionarily successful, bacteria need to be competitive both under 
limited and excessive supply of carbon and energy resources. They have to be able to 
efficiently select the preferred, most energetic carbon source out of a mixture of nutrients 
available in the environment at a given moment. Theunderlying regulatory mechanisms 
have been extensively studied in Escherichia coli as well as in Bacillus subtilis, the model 
Gram-positive bacterium [1, 2].  
Bacillus subtilis is a soil bacterium, that can use at least 18 different mono- or 
disaccharides as sole sources of carbon and energy, as it produces extracellular hydrolases 
to digest polysaccharides of plant biomass [3]. The most preferred carbon and energy 
source is glucose and the expression of the genes involved in the catabolism of alternative 
nutrients is strictly controlled by two key mechanisms: carbon catabolite repression and 
induction. The carbon catabolite repression mechanism ensures that the genes encoding 
enzymes for the utilization of the non-preferred carbon sources are not expressed in the 
presence of the preferred nutrient. Additionally, the more specific induction mechanism 
ensures that genes for alternative catabolic pathways are not expressed, unless the 
respective alternative substrate is present in the environment. This regulation network 
includes a wide range of specific repressor proteins a d functions at the level of 
transcription of metabolic operons [1, 4].  
 
5.1.1 Carbohydrate catabolism  
B. subtilis excretes various enzymes including glucanases, proteases and nucleases to 
decompose complex nutrients present in the soil. Amylases and glucanases are of major 
importance, as they degrade glucose polymers and pro uce maltodextrins, maltose, and 
glucose, the most preferred nutrient. The resulting mono-, di-, or oligosaccharides are 
imported into the cell by facilitated diffusion, secondary active transporters, ATP-binding 
cassette transporters, or the phosphoenolpyruvate: sugar phosphotransferase system (PTS), 
which phosphorylates the transported substrates. The PTS system not only transports 
nutrients into the cell, but also plays role in signal transduction. The system consists of two 
universal proteins: enzyme I and phosphocarrier protein (HPr), and of numerous 
 15 
substrate-specific enzymes II. Enzymes II are protein complexes that perform the actual 
transport of the nutrients which are simultaneously phosphorylated by the cooperative 
action of enzyme I, HPr, and components of enzyme II complex [1, 3].   
Once in the cell, the di- or oligosaccharides or their phosphorylated forms are cleaved 
by the respective glycosidases or phosphoglycosidases, respectively. The 
non-phosphorylated products are phosphorylated by kinases and enter the pentose 
phosphate pathway and glycolysis, yielding pyruvate which is converted by pyruvate 
dehydrogenase complex to acetyl-coenzyme A to be further metabolized in the 
tricarboxylic acid cycle. Apart from sugars, B. subtilis can also import and utilize various 
carbohydrate derivatives, such as aminosugars, hexitols, hexuronic acids, deoxyribose, and 
glycerol [3].  
 
5.1.2 Carbon catabolite repression of catabolic operons  
Carbon catabolite repression mechanisms ensure that cat bolic genes and operons for 
alternative nutrients are not transcribed as long as preferred carbon and energy sources are 
present in the environment. This regulation can be achieved by three mechanisms: 
(1) control of the catabolic genes transcription by global sensor proteins registering the 
presence of preferred nutrients, (2) regulation of the intracellular availability of the 
catabolic genes inducers (inducer exclusion), or (3) induction prevention by 
operon-specific regulators controlled by preferred nutrients [2, 5, 6]. B. subtilis combines 
these mechanisms while using the PTS system and HPr kinase as the intracellular sensors 
of nutrient availability that trigger further carbon catabolite repression pathways [1, 7].  
HPr can be phosphorylated by an ATP-dependent HPr kinase activated by specific 
metabolites, which leads to decreased PTS activity. HPr kinase functions both as kinase 
and phosphatase. The kinase activity is stimulated by glycolytic intermediates and 
inhibited by inorganic phosphate, which also stimulates the phosphatase activity of HPr 
kinase. Phosphorylated HPr protein can than act as a cofactor of the PTS system, or 
phosphorylate other regulatory proteins. Phosphorylated HPr binds to the C-terminal 
effector-binding domain of catabolite control protein A (CcpA), a transcriptional regulator 
that binds through its N-terminal DNA-binding domain to operator palindromic sequences 
cre (catabolite-responsive element) in various operons and genes. The interaction of CcpA 
with the phosphorylated HPr downregulates the expression of catabolic genes by binding 
the cre elements or by direct contact of the HPr-bound CcpA with RNA polymerase. CcpA 
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can also function as a transcriptional activator of glycolytic and overflow metabolism 
genes in the presence of preferred nutrients by interac ing with the cre sites located 
upstream of the promoters of their operons, which enables very fast growth [1, 7].  
The presence of preferred nutrients in the cell can prevent transport or formation of 
effector molecules inducing the expression of catabolic operons. An example of this 
inducer exclusion mechanism is B. subtilis glp operon, where the PTS is involved in 
formation of the inducer glycerol-3-phosphate. Monoph sphorylated HPr can 
phosphorylate glycerol kinase and enhance its kinase activity [8]. The concentration of this 
monophosphorylated form of HPr is lower in the presence of preferred carbon sources, as 
it is depleted as a cofactor of the PTS by the nutrient-specific enzyme II or by 
phosphorylation of other HPr residues by HPr kinase. Therefore, glycerol kinase is less 
active and lower amount of the inducer glycerol-3-phosphate is formed under carbon 
catabolite repression conditions [1, 9].  
Several catabolic operons for the non-preferred nutrients are positively regulated by 
activators or antiterminators in the presence of the inducer. Transcriptional factors of this 
type are inactivated in the absence of the inducer by the PTS-dependent phosphorylation at 
their phosphotransferase regulator domains (PRDs). Some of these proteins, which are 
subject to carbon catabolite repression, are only active (binding DNA) when 
phosphorylated at other sites in their PRDs by the monophosphorylated HPr protein. This 
additional HPr-dependent phosphorylation of the PRDs prevents induction of the catabolic 
operons for the non-preferred nutrients [1].  
 
5.1.3 Induction of catabolic operons  
The operons coding for the enzymes required for the catabolism of specific nutrients 
are not expressed, unless the respective carbon source is present in the environment. This 
process is controlled at the level of transcription by three different mechanisms: 
transcriptional repressors, activators, and antiterminators [3].  
Transcriptional repressors in B. subtilis negatively control expression of operons for the 
catabolism of numerous nutrients including glucose, glucosamine, N-acetyl-glucosamine, 
trehalose, glucomannan, fructose, fructosamine, inositol, gluconate, arabinose, ribose, 
deoxyribose, xylose, and galactose. In the absence of the nutrient, the repressor binds 
through the N-terminal DNA-binding domain to the DNA operator site, usually upstream 
of the operon. In the presence of the effector (the nutrient or its catabolic intermediate), the 
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repressor binds the effector through the C-terminal effector-binding domain and the 
resulting conformational change results in lower affinity towards the DNA operator or 
even promotes dissociation of the repressor from the operator (see Figure 1) [1].  
 
 
Figure 1: Regulation of catabolic genes expression by a transcriptional repressor  
The molecular-switch function of a transcriptional repressor is schematically illustrated.  
 
 
Transcriptional activators regulate the expression of catabolic genes for nutrients such 
as oligo-β-glucoside, fructose, mannitol, mannose, and glucitol and can be divided into two 
classes: (1) activators functional only in the complex with their specific inducer and 
(2) activators modulated by phosphorylation dependent on the presence of the substrate. 
Vast majority of B. subtilis activators are phosphorylation-regulated and can be further 
subclassified as activators of the σA- or σL-dependent promoters. The activator proteins 
typically contain an N-terminal DNA-binding domain and several other domains with 
additional functions and conserved phosphorylation sites, which are phosphorylated by 
PTS components (HPr or enzyme II) in the absence of the respective nutrient, which 
results in the inactivation of the activator protein [1, 10].  
Transcriptional antiterminators regulate the expression of catabolic operons coding for 
utilization of nutrients including glucose, sucrose, β-glucosides, and glycerol. Most of the 
transcriptional antiterminators consist of an N-terminal RNA-binding domain and two 
PRD domains. The antiterminator-regulated operons are tr nscribed constitutively, but the 
transcription stops at transcriptional terminator sequences located upstream of the open 
reading frames. The 5’-parts of the terminators can be incorporated into stem-loop 
structures formed by ribonucleic antiterminator inverted repeat sequences (RATs). The 
antiterminator regulatory proteins bind the RAT sequ nces through their RNA-binding 
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domains, and their binding promotes transcription. In the absence of the specific nutrient, 
the PRDs are phosphorylated by PTS components (HPr or enzyme II), resulting in 
inactivation of the respective antiterminator protein [1, 10].  
 
5.1.4 Metabolic repressors in B. subtilis  
Majority of the transcriptional repressors regulating catabolic genes in Bacillus subtilis 
that have been characterized so far are members of foll wing families of prokaryotic 
transcriptional factors: DeoR, GntR, SorC or LacI (see Table 1). The classification of the 
families is based on the sequence similarity of the N-terminal helix-turn-helix 
DNA-binding domains of the repressors. These conserved DNA-binding domains are 
combined with C-terminal effector-binding domains belonging to various structural 
families. The C-terminal domains are responsible for e fector molecule recognition and for 
repressor oligomerization (see Figure 1, Table 1). This chimeric domain organization 
allows for great structural and functional variety of metabolic repressors. Several 
B. subtillis repressors have been studied on the structural leve by X-ray crystallography 
(Table 1), usually as individual domains with the exception of the recently determined 
crystal structure of the full-length repressor NagR, also in the complex with its DNA 
operator [11, 12].  
 
Table 1: Repressors in carbohydrate utilization in Bacillus subtilisa 
Sugar Operon Repressor DBD family  (PDB code) 
EBD family  
(PDB code) 
Arabinose araABDLMNOPQ-abfA AraR GntR (4EGY [13]) LacI (3TB6 [14]) 
Deoxyribose dra-nupC-pdp DeoR SorC SorC 
Fructosamine yurPONML FrlR GntR HutC (2IKK) 
Fructose fruRBA FruR DeoR DeoR 














CggR SorC SorC (2OGK [15]) 




GntR (2WV0 [11], 
4WWC [12]) 
HutC (2WV0 [11], 
4WWC [12]) 
Ribose rbsRKDACB RbsR LacI LacI 
Trehalose trePAR TreR GntR HutC (2OGG [16]) 
Xylose xylAB XylR ?b NagC/XylR 
acompiled from [1], Pfam database [17], database of transcriptional regulation in Bacillus subtilis (DBTBS 
[18]), Protein data bank (PDB, http://www.rcsb.org), and UniProt (www.uniprot.org); bdomains were not 
unambiguously classified; DBD, DNA-binding domain; EBD, effector-binding domain.  
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5.1.5 Transcriptional regulator DeoR form B. subtilis  
Bacillus subtilis can utilize deoxyribonucleosides and deoxyribose a a source of 
carbon and energy. The deoxyribonucleosides are imported into the cellby nucleoside 
uptake protein C (NupC) and phosphorolytically cleaved by pyrimidine nucleoside 
phosphorylase (Pdp), yielding a base and deoxyribose-1-phosphate, which is converted to 
deoxyribose-5-phosphate and further processed by deoxyriboaldolase (Dra) to 
acetaldehyde and glyceraldehyde-3-phosphate. The genes ncoding these three key 
enzymes of this catabolic pathway are grouped into the dra-nupC-pdp operon, which is 
under negative transcriptional control of the deoxyribonucleoside regulator, DeoR [19]. 
Another enzyme involved in this catabolic pathway is phosphodeoxyribomutase (Drm) 
which converts deoxyribose-1-phosphate to deoxyribose-5-phosphate. This enzyme is 
encoded by the drm gene located far from the dra-nupC-pdp operon in B. subtilis and its 
expression is therefore probably modulated by some th r regulatory protein [19].  
The deoR gene is located immediately upstream of the dra-nupC-pdp operon [19] and 
codes for the 313 amino acids long DeoR repressor protein that recognizes a palindromic 
operator sequence located between the positions -60 and -43 relative to the transcription 
start site for the dra-nupC-pdp operon. Also, a direct repeat sequence identical to the 
3′-half of the palindrome, that might be another possible DeoR binding site, is located 
downstream to the palindrome (see Figure 2, Table 2) [20].  
The dra-nupC-pdp operon is subject to another negative regulation mechanism, carbon 
catabolite repression by glucose [20, 21]. The opern carries one cre element, located 
downstream of the dra transcription start site (Figure 2). The catabolite repression by HPr 
can be in this case substituted by the homologous CrH protein [21], which is also 
phosphorylated by HPr kinase and then induces CcpA binding to cre, similarly to 
phospho-HPr [22, 23]. Mfd protein is also involved [21], which is a strand-specific DNA 






Figure 2: Schematic overview of the deoR-dra-nupC-pdp operon  
Genome positions of the individual genes in the minus DNA strand are schematically illustrated: deoR is the 
deoxyribonucleoside regulator gene, dra is the deoxyriboaldolase gene, nupC is the nucleoside uptake protein 
C gene, and pdp is the pyrimidine nucleoside phosphorylase gene. Promoter and operator sites for RNA 
polymerase σ-43 factor (σA), deoxyribonucleoside regulator (DeoR), and catabolite control protein A (CcpA) 
are also indicated in colors. Compiled from [18, 19].  
 
 
Table 2: Promoter and operator sites of the dra-nupC-pdp operon in Bacillus subtilis   
Factor Location Binding sequence (cis-element)a Ref. 
CcpA +60 – +82 GCTTGAAACCGCATACACAAAA [19] 
DeoR -60 – -22 
ATTGAACAAAAT TTCAATTACCAATTTACAT
ATGTTCAA 
[19, 20, 25] 





aThe minimal operator binding sites for catabolite control protein A (CcpA) and deoxyribonucleoside 
regulator (DeoR) are highlighted in red. Compiled from [18].  
 
 
Both deoxyribose-1-phosphate and deoxyribose-5-phosphate are suggested to function 
as inducers of the catabolic operon, but only deoxyribose-5-phosphate appears to be the 
true effector [20]. Despite the participation of Pdp and Drm in the catabolism of 
pyrimidine ribonucleosides, no induction of expression of the dra, pdp, or drm genes has 
been observed in B. subtilis in the presence of ribonucleosides [19]. The carbon catabolite 
repression of the dra-nupC-pdp operon only occurs when the operon is not repressed by 
DeoR [21]. Also, neither CcpA, nor DeoR binds strong enough to totally prevent 
expression of the dra-nupC-pdp. This might be a protective mechanism against the toxic 
effects of deoxyribose-5-phosphate [19], or it may also be a result of the action of 
phosphodeoxyribomutase, which constitutively produces very low amounts of 
deoxyribose-5-phosphate from deoxyribose-1-phosphate [26].  
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The DeoR regulator from Bacillus subtilis is not related to the DeoR from Escherichia 
coli [18, 25], which belongs to the DeoR family and regulates the deo operon and has been 
studied in great detail [27]. Although both DeoR regulators from B. subtilis and E. coli 
contain a similar helix-turn-helix motif typical for DNA-binding proteins [28, 29] there is 
very little sequence similarity between them, and there is no similarity between their DNA 
operator sites [20, 25, 30]. The N-terminal DNA-binding domain of the B. subtilis DeoR is 
homologous to the SorC family of regulator proteins from various bacteria species that 
play role in transcriptional regulation of sugar alcohol catabolism genes [25]. The 
C-terminal effector-binding domain of B. subtilis DeoR is homologous to the SorC-type 
regulators of glucose metabolism genes that probably recognize 
glyceraldehyde-3-phosphate as the effector molecule [25]. The domain organization of 




Figure 3: Domain organization of DeoR 
The modular domain organization of deoxyribonucleoside regulator (DeoR) is schematically illustrated with 
residue numbers indicating domain boundaries according to [17]. 
 
 
The only one SorC-type transcriptional regulator characterized so far in B. subtilis is 
the central glycolytic genes regulator, CggR [18]. The sequence identity of DeoR and 
CggR is 20% (according to the UniProt Align tool at www.uniprot.org/align). Crystal 
structure of the CggR effector-binding domain, which s also classified as the SorC-type 
effector-binding domain, has been determined and reveal d a double-Rossmann fold core 
with three accessory peripheral subdomains involved in repressor oligomerization and 
effector binding. CggR binds four different ligands: fructose-1,6-bisphosphate, 
dihydroxyaceton phosphate, glucose-6-phosphate, and fructose-6-phosphate. Each of these 
ligands induces individual specific conformational changes that influence the dimer 
interface in the effector-binding domain and affect the distribution of the repressor 




5.2 CD44 antigen 
The CD44 antigen, a type I transmembrane glycoprotein also known as lymphocyte 
homing/adhesion receptor, epican, or Hermes antigen, was first described in 1983 [31-33]. 
CD44 is the principal cell receptor for hyaluronate [34], which is a major component of 
extracellular matrix. CD44 can also mediate binding to other components of extracellular 
matrix, including fibronectin, collagen, laminin, and fibrin and to several cell-surface 
ligands, such as E-, P-, and L-selectin [35-39]. Intracellular portion of CD44 is involved in 
signaling pathways [39, 40]. It interacts through ankyrin adaptor protein with spectrin and 
is involved in hyaluronate-dependent cell adhesion and motility [41]. Other binding 
partners of the intracellular CD44 domain are ezrin, radixin and moesin (ERM proteins) 
involved in the regulation of cell migration, shape, and protein resorting in the plasma 
membrane [42]. The ERM proteins mediate the interacion of CD44 intracellular domain 
with filamentous actin [43] which results in CD44 clustering [39, 40].  
CD44 is expressed in most mammalian tissues, mainly in the gastrointestinal tract, 
skin, spleen, and leukocytes. Lower expression level can be observed in erythrocytes, 
neurons, and brain. CD44 is not expressed in kidney, h patocytes, and mature thymocytes 
[32, 44]. The expression of CD44 on blood cell progenitors is strictly regulated during 
differentiation and it can be induced in many cell types only after cell activation [45, 46].  
 
5.2.1 CD44 function 
The CD44 receptor is involved not only in cell adhesion, but also in cell survival and 
proliferation, growth factor presentation, apoptosis, and cell motility and migration [47]. 
CD44 is a key player in lymphocyte trafficking and recirculation, including lymphocyte 
extravasation and homing to the peripheral lymphoid organs or the site of inflammation. 
These processes are initiated by a CD44-mediated rolling adhesion of lymphocytes to 
endothelial cells presenting hyaluronate (see Figure 4) [48]. CD44 also mediates and 
regulates the mobilization and distribution of blood cell progenitors during hematopoiesis 
in bone marrow [39, 49]. CD44 is also important for hyaluronate metabolism as it executes 
hyaluronate internalization which allows subsequent hyaluronate degradation by acid 
hydrolases within low-pH cellular compartments such as lysosomes [50]. This process is 





Figure 4: CD44 in lymphocyte homing  
Schematic representation of CD44-mediated rolling of lymphocytes on endothelium is shown. T-cell capture 
and rolling are mediated by CD44 (orange) recognitio  of hyaluronate (green) presented on the endothelial 
cells. Firm adhesion is induced by the binding of integrins (dark blue) activated by inflammatory chemokines 
(red) to their counter-receptors (light blue) on the endothelium, which results in T-cell diapedesis, 
extravasation, and migration to the site of inflammation. Amended from http://www.glycoforum.gr.jp/.   
 
 
5.2.2 CD44 structure 
The 363 amino acids long CD44 glycoprotein (residues 21-383; see Figure 5) belongs 
to the cartilage Link protein superfamily [52, 53]. The extracellular portion of CD44 
comprises the N-terminal 158 amino acids long extended Link domain coded by exons 
S1-S4 followed by the 112 amino acids long stem region coded by exons S5, S6, and S7 
[54]. The stalk-like structure can be enlarged by the insertion of variable exon products 
V1-V10 between residues 222 and 223 due to alternative splicing [45, 55]. The 
extracellular portion of CD44 is followed by the 21 amino acids long hydrophobic 
transmembrane region coded by exon S8. Exons S9 and S10 code for the 72 amino acids 
long intracellular C-terminal domain [56, 57].  
CD44 is subject to posttranslational modification. The N-terminal part is heavily 
N-glycosylated (Asn25, 57, 100, 110, and 120 [58]), the membrane-proximal serine- and 
threonine-rich extracellular region is O-glycosylated, an intracellular serine residue can be 
phosphorylated, and two conserved cysteine residues in the transmembrane domain and in 
the membrane-proximal cytoplasmic region can be palmitoylated [45, 51, 57]. The stem 
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region contains putative proteolytic cleavage site that allows for CD44 shedding [59]. 
After the ectodomain shedding, the intracellular domain can be released by an 
intramembrane presenilin-dependent γ-secretase cleavage [60] and the released 
cytoplasmic CD44 domain can then function as a transcription factor in the nucleus, 
promoting expression of numerous genes [61].  
 
 
Figure 5: CD44 gene and protein structure  
CD44 gene composition is shown comprising 10 constant exons (S1-S10) and 10 alternatively spliced 
variable exons (V1-V10), coding for the extracellular, transmembrane (TM), and cytoplasmic (CP) portions 
of CD44. The CD44 protein products, the standard (CD44s) and variant (CD44v) isoforms are schematically 
illustrated with the color coding indicating the extracellular, transmembrane, Link, and stalk domains, the 
variable exons, and also the interaction sites for ankyrin and for the ezrin, radixin, and moesin (ERM) 
proteins. N-glycosylation sites are represented by gre  circles, O-glycosylation sites by orange circles, and 
glycosaminoglycan-binding sites by yellow circles. S-S indicates disulfide bonds. Adapted from [57].  
 
 
5.2.3 Hyaluronate-binding domain of CD44 
The N-terminal extended Link domain is responsible for hyaluronate binding and 
therefore, it is often referred to as the CD44 hyaluronate-binding domain (CD44 HABD). 
CD44 HABD binds hyaluronate molecules in a wide range of molecular weights. The 
minimum length of hyaluronate chain to be recognized by HABD is a hexamer and optimal 
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binding was achieved for hyaluronate octamer [62, 63]. Three-dimensional structures of 
mouse and human HABD have been determined by X-ray c ystallography and NMR, 
respectively [62-64]. These structures revealed that HABD has a novel type of C-lectin 
fold, which can be designated as: β0 - β0’ - β1 - α1 - α2 - β3 - β4 - β5 - β6 - β7 - β8 - β9 - 
α3 (see Figure 6). The 100 amino acids long hyaluronate-binding Link module (residues 
32-132, in bold) contains two highly conserved disulf de bridges and its sequence is 
generally conserved within the family of hyaluronate-binding proteins (80 – 90% sequence 
similarity) [33, 40, 45, 65]. Link module is the most evolutionarily conserved part of the 
whole CD44 antigen [66, 67]. In contrast to other Link superfamily members, the Link 
module in CD44 HABD is equipped with an extension lbe formed by β0 and β0’ at the 
N-terminus and by β7, β8, β9, and α3 at the C-terminus of HABD [62]. This extension is 
crucial for structural integrity as it contains an dditional disulfide bridge important for the 
correct folding of the Link module [68] and it also plays an important role in hyaluronate 
binding [65, 69]. The key interactions for the hyaluronate binding to human CD44 are 
hydrogen bonds with residues Arg41, Tyr42, Arg78 a Tyr79 from the Link module, but 
residues Arg29, Arg150, Arg154, Lys158 a Arg162 from the extension lobe also take part 
in hyaluronate binding, suggesting a more complex hyaluronate-binding mode than in the 
case of other hyaluronate-binding proteins of the Link family [62, 63, 65].   
The solution structure of HABD in complex with hyaluronate determined by NMR [64] 
unraveled a major allosteric conformational change in HABD induced by the ligand 
binding (Figure 6): β9 strand and α3 helix become an unstructured random coil, and β8 and 
β0 strands are repositioned relative to each other, which results in an enhanced flexibility 
of the C-terminus of the HABD [64]. The ligand-free state of HABD is referred to as 
“ordered” (O) and the ligand-bound state as “partially disordered” (PD). The O-state 
structure of the ligand-bound murine CD44 HABD has been also captured by X-ray 
crystallography, probably because the rigid ordered conformation is more likely to form 
crystal contacts [63]. There is a two-state equilibrium between the O- and 
PD-conformational states of CD44 HABD and both conformations are capable of 
hyaluronate binding [70]. However, the PD-conformation exhibits higher affinity towards 
hyaluronate and it is also more resistant to cell dtachment from a hyaluronate-coated 
surface in comparison to the O-conformation [70]. This conformational equilibrium has 
been proposed to be a mechanism essential for the proper CD44-mediated cell rolling, 
specifically for the formation of new contacts of the CD44 receptor with hyaluronate at the 
cell rolling front and for their disruption at the r ar edge [70]. The ligand-induced shift in 
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the equilibrium in the favor of the PD-conformation also results in the elongation of the 
stalk-like membrane-proximal region of CD44. This makes the stem region more easily 
accessible to matrix metalloproteases and thus enhances the proteolytic susceptibility of 
the cleavage sites [64], which results in hyaluronate-induced HABD shedding and  




Figure 6: Structures of the CD44 hyaluronate-binding domain  
A: CD44 hyaluronate-binding domain (HABD) topology is depicted in a cartoon diagram of the ligand-free 
CD44 HABD (left, PDB code 1POZ [62]) and hyaluronate-bound CD44 HABD (right, PDB code 2I83 [64]). 
Secondary structure elements are labeled; α-helices are in red, β-strands are in yellow, and random coil is in 
green. B: Hyaluronate-induced structural changes ar depicted in a cartoon-surface diagram of the ligand-free 
CD44 HABD (left, PDB code 1POZ [62]) and hyaluronate-bound CD44 HABD (right, PDB code 2I83 [64]). 
The Link module is shown in blue and the extension lobe in gray. The hyaluronate octamer from the crystal 
structure of the hyaluronate-bound murine CD44 HABD (PDB code 2JCQ [63]) is superposed onto the 





Figure 7: Hyaluronate-induced CD44 shedding  
Schematic representation of the hyaluronate-induced structural changes (see also Figure 6) in CD44 
hyaluronate-binding domain (HABD) is shown, which promotes proteolytic cleavage in the stem region 
resulting in CD44 ectodomain shedding. Illustrated according to [64, 70].  
 
 
5.2.4 CD44 regulation 
Hyaluronate binding to CD44 is regulated by a number of factors including cell 
activation state, receptor clustering, glycosylation pattern, phosphorylation of intracellular 
Ser291 and receptor dimerization through intramembrane cysteine residues [39, 73-76]. 
Especially the O-glycosylation pattern together with the cytoplasmic tail of CD44 can 
affect membrane subdomain localization which can modulate the interaction of CD44 
with hyaluronate [77]. CD44 glycosylation also directly controls its binding capacity to 
fibrin and immobilized fibrinogen [38, 78]. Moreover, CD44 has an inducible character. It 
is in an inactive (low-affinity) state on the surface of resting T-cells and monocytes and it 
only binds hyaluronate after the transition to a high-affinity state due to cytokine activation 
or T-cell activation through the TCR-CD3 [46]. The transition to the high-affinity state is 
induced by enzymatic removal of terminal sialic acids from the N-linked glycosylation 
chains on Asn25 and Asn120 [75, 79]. This mechanism targets selected populations of 
peripheral blood cells to the inflammation site, where they recognize hyaluronate presented 
on the surface of cytokine-activated endothelial cells and leave the blood stream [62, 63].  
Some of the CD44 functions are determined by alternative splicing of the CD44 
precursor mRNA [57, 80]. The CD44 gene, located on chromosome 11, spans 50 thousand 
base pairs of genomic DNA [40] and comprises 20 exons, out of which 10 exons are 
variable (V1-V10; see Figure 5) [57, 80]. Omitting all these exons gives rise to the 
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standard or hematopoietic form CD44s (80-85 kDa, 270 extracellular amino acids [45, 
56]), which is expressed in most cell types [81], typically on activated leukocytes, where it 
plays role in their adhesion and trafficking to the inflammation site [82]. The variable 
exons code for CD44 membrane-proximal region and give rise to at least 20 variant mRNA 
molecules and at least six out of them were observed also in the form of variant isoform 
protein product CD44v [82]. Some of the variant isoforms exhibit constitutive 
hyaluronate-binding activity [73, 83]. Inclusion ofexon V3 creates a site for chondroitin 
sulfate and heparan sulfate modification. This modification enables binding of several 
growth factors and chemokines, which amplify the immune response [84, 85]. Inclusion of 
exon V6 creates a binding site for hepatocyte growth factor and vascular endothelial 
growth factor [85, 86].  
 
5.2.5 CD44 in pathology 
CD44 also plays a role in various types of pathological processes, such as extensive 
inflammatory diseases [87] and cancer, especially in tumor-cell migration and metastasis 
[47, 72, 81, 88]. Autoimmune inflammatory disorders a e characterized by elevated counts 
of lymphocytes bearing the activated high-affinity-s ate CD44 [89]. This phenomenon has 
been observed in patients suffering form lupus eryth matosus and chronic arthropathies 
[90] and in rheumatoid arthritis patients [91]. CD44 has therefore been suggested to play 
a crucial role in the maintenance and propagation of autoimmune inflammatory diseases 
[45].   
Expression of CD44 variant isoforms can induce metasta ic phenotype in locally 
growing tumor cells [88, 92] and usually correlates with bad prognosis [88]. Inclusion of 
variant exon V6 has been shown to induce tumor metastasis [92] which is probably caused 
by a loss of contact with the neighboring cells due to altered adhesion properties of the 
cells. Proteolysis of the extracellular matrix induced by CD44 variant isoforms [71, 93] 
facilitates the detachment of tumor cells from the umor site and their spread outside the 
original tumor.  
Another explanation for the metastatic behavior might be an increased mobility of the 
cells along the hyaluronate-rich extracellular matrix due to the overexpression of CD44 
standard variant CD44s [94]. A significant number of acute lymphoblastic leukemia cases 
exhibit very high or low CD44 expression on leukemic B-cells when compared to normal 
B-cell progenitors. This can be used for the detection of minimal residual disease [39, 95, 
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96]. Low expression of CD44s has been correlated with the aggressive phenotype of some 
solid tumor types [97-99]. CD44 in cancer cells promotes angiogenesis and the tumor 
growth, as CD44 has proliferative and anti-apoptotic effects in general [67, 80]. Expression 
of CD44 is important in the progression of many tumor types [81], is often observed on 
cancer stem cells [100], and can be a marker of poor rognosis [101]. The cytostatic and 
pro-apoptotic function of p53 tumor suppressor protein [102] is connected with the 
inhibition of CD44 expression. The p53 factor binds to the promoter region of the CD44 
gene and thus prevents excess mitotic activity in the cell which prevents tumor growth 
[103]. CD44 interacts with the HER2 tyrosine kinase from the EGF receptor family. 
Overexpression of HER2 by breast and ovarian cancer cells is an indicator of poor 
prognosis. CD44s isoform can form interchain disulfde bonds with HER2 and hyaluronate 
binding to CD44 then stimulates the tyrosine kinase ctivity of HER2 which triggers 
signaling pathways that promote cell growth and proliferation [49, 104]. Moreover, CD44 
receptor clusters are capable of recruiting matrix metalloprotease 9 to the cell membrane 
and thus localizing its proteolytic collagenase activity to the tumor cells. This leads to 
extracellular matrix degradation which by itself facilitates tumor growth but it also releases 
growth factors and angiogenic factors sequestered in the extracellular matrix, which further 
stimulates tumor progression [105].  
 
5.2.6 CD44 as a target in cancer therapy  
Many approaches in cancer therapy are focused on CD44. CD44 has been identified as 
a marker of cancer stem cells which represent only a minor population of tumor cells, but 
are essential for tumor progression and tumor survival during treatment. Cancer stem cells 
often resist the treatment and this causes cancer relapse or recurrence at distal sites [106]. 
Cancer initiating cells might thus be targeted through CD44 [57].  
One of promising therapeutic approaches is CD44 blocking, the abruption of CD44 
interaction with hyaluronate [107].  Hyaluronate induces anti-apoptotic signaling pathways 
through interaction with the activated CD44 during i flammation and tissue healing or 
with the constitutively active CD44 on cancer cells [73, 107]. The CD44 inactive state 
structure on normal cells is different as it is notac ivated by the specific conditions of the 
environment [88]. The constitutive hyaluronate-binding by CD44 can be exploited in 
cancer therapy by four different approaches [107]: (1) small hyaluronate oligomers can be 
used to compete with the endogenous hyaluronate, (2) soluble CD44 or other 
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hyaluronate-binding proteins can be used to outcompete the endogenous cell-surface CD44 
for hyaluronate binding, (3) the post-transcriptional expression of CD44 variant isoforms 
can be inhibited using CD44 siRNAs, and (4) hyaluronate binding can be blocked by an 
anti-CD44 antibody recognizing the hyaluronate-binding site [108-112]. Recently, another 
approach emerged: (5) first small-molecular inhibitors of the hyaluronate binding to CD44 
have been identified by a combinantion of fragment screening and structure-based 
optimization of the lead compounds. These compounds are based on 
1,2,3,4-tetrahydroisoquinoline and they might be potential therapeutic agents in cancer, but 
also in chronic inflammatory diseases [113].  
Small hyaluronate oligomers or antibodies can be further equipped with cytostatic 
drugs, possibly encapsulated in liposomes, internalized through CD44 [50] and activated 
inside the tumor cell [114-116]. This approach also increases the drug solubility [116]. The 
next part is focused on the use of antibodies in CD44-targeted cancer therapy.  
 
5.2.7 Anti-CD44 antibodies in cancer therapy 
Known anti-CD44 antibodies recognize a wide variety of antigenic determinants in the 
CD44 molecule [117]. The standard variant CD44s contains three distinct groups of 
antigen epitopes. Antibodies recognizing epitope group 1 inhibit T-cell clustering, 
antibodies recognizing epitope group 2 block hyaluronate binding to CD44, and antibodies 
recognizing epitope group 3 block lymphocyte adhesion to the epithelium of blood vessels 
[39, 44]. Antibodies recognizing CD44 can be used to block hyaluronate binding to CD44 
and disrupt its interactions with the extracellular matrix [117, 118] or even induce CD44 
ectodomain shedding [119]. Activating antibodies can be used to induce CD44 
pro-apoptotic signaling [120-122], and anti-CD44 antibodies in general can be used for 
targeting anti-cancer active substances to the tumor site [123-125].  
Several anti-CD44 antibodies targeting cancer stem c lls show a promising potential in 
the preclinical stage [126, 127]. Murine monoclonal antibody H90 activates CD44 
signaling that triggers pro-apoptotic and proliferation-inhibitory pathways in human acute 
myeloid leukemia [121, 122, 128, 129]. Murine monoclonal antibody P245 reduces tumor 
growth in the mouse model of human basal-like breast c ncer and was able to eliminate 
cancer stem cells and thus prevent breast cancer relapse [130]. Murine monoclonal 
antibody H4C4 inhibits human pancreatic tumor growth, metastasis, and recurrence in 
mouse xenografts by inhibiting specific CD44 signali g pathways [127]. Recombinant 
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human monoclonal antibody GV5 against CD44v8-v10 isoform completely inhibited 
tumorigenesis of human cervix and larynx carcinomas in mouse models, by inducing 
antibody-dependent cell cytotoxicity mechanisms [131]. Recombinant humanized antibody 
RO5429083/RG7356 recognizes a glycosylated part of CD44 present in all CD44 
isoforms. The antibody interferes with hyaluronate binding, but does not induce CD44 
shedding. It inhibits the growth of head and neck squamous cell carcinoma tumor cells, 
breast cancer cells, and chronic lymphocytic leukemia cells in vitro and in mouse 
xenografts [118, 132, 133]. The RO5429083/RG7356 antibody has recently reached phase 
I clinical trials in patients with CD44-positive malignant solid tumors and a study with the 
antibody alone or an immunotoxin conjugate of the antibody with cytarabine in patients 
suffering from acute myeloid leukemia [127].  
The use of antibodies targeting the CD44v6 variant soform appears to be the most 
successful approach in CD44-based cancer immunotherapy [134, 135]. For example, 
monoclonal antibody 1.1ASML against CD44v6 has been shown to block metastases 
formation in animal models of cancer [119]. These antibodies are especially potent in the 
form of radioimmunoconjugates or immunotoxin conjugates. Several clinical phase I trials 
were performed with murine (U36, BIWA 1), chimeric (chU36), and humanized (BIWA 4) 
monoclonal antibodies recognizing CD44v6 isoform [135]. Murine antibody U36 
conjugated with technetium 99mTc was successfully tested as a diagnostic tool for the 
detection of lymph node metastases [136], however, it induced human anti-mouse immune 
response in later radioimmunotherapy studies with the rhenium 186Re-conjugate [137] and 
had to be chimerized for further therapeutic applications [138]. The phase I study with the 
chimerized chU36 antibody has shown reduced adverse immune response while 
maintaining the effective antibody responses [139-142]. Murine monoclonal antibody 
BIWA 1 conjugated with 99mTc has been proven an effective and relatively safediagnostic 
tool in a radioimmunoscintigraphy study [143]. Due to the human anti-mouse adverse 
immune response in the patients [143], a humanized version, BIWA 4 was constructed for 
further therapeutic applications, also known as Bivatuzumab. Bivatuzumab reached the 
phase I clinical trials in the form of a radioimmunoconjugate with 186Re [123, 144]. 
Bivatuzumab was also tested in phase I clinical trials in the form of an immunotoxin 
conjugate with the cytotoxic drug mertansine. Although these trials seemed very 




5.2.8 Monoclonal antibody MEM-85 against CD44 
Murine monoclonal antibody MEM-85 of IgG2 class recognizes the CD44 antigen 
[149]. It was raised against peripheral blood monocytes of a patient suffering form large 
granular lymphocyte leukemia [149]. The antibody reacts with all peripheral blood 
monocytes, with granulocytes, and with cell lines including CEM, MOLT-4, ARH-77, 
HEL, HL-60. MEM-85 reacts very weekly or it does not react at all with cell lines such as 
Jurkat, Nalm-6, Daudi, and KM3 [32].  
MEM-85 has been shown to block hyaluronate binding to CD44 [149, 150] and the 
antibody binding also induces CD44 shedding, similar to that induced by hyaluronate 
binding [151]. The HABD epitope recognized by MEM-85 has not yet been 
unambiguously identified. The epitope is supposed to be localized in the N-terminal part of 
the HABD [32, 33, 44] and mutational analysis results suggest that residues Lys38, Arg41, 
and Tyr42 are important for MEM-85 binding [33]. This represents an epitope from the 
epitope group 2 [32, 44, 150] discussed above. Some consider the MEM-85 epitope to be 
structural [33], but others have observed MEM-85 binding to SDS-denatured CD44 under 
non-reducing conditions, which suggests a sequential epitope, stabilized by a disulfide 
bridge [32].  
Antibody MEM-85 might play an important role in diagnostics of some types of 
malignancies, especially for the detection of minimal residual disease. It might also be of 
therapeutic interest, as it has been shown to inhibit lung cancer cells growth in murine 
models (Godar, S., personal communication). This antibody can also be used as a tool for 
better understanding hyaluronate binding to CD44 and of the subsequent cellular 
processes, which would be useful for structure-based d sign of inhibitors of the 
hyaluronate binding.  
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6 Aims of the study 
 
This work is a part of two long-term projects: (1) X-ray crystallographic studies of 
bacterial transcription factors and (2) recombinant ibody fragments targeted against 
therapeutically relevant human antigens.  
Structural studies of selected metabolic repressors fr m the model bacterium Bacillus 
subtilis aim to elucidate the mechanisms of metabolite repression on the molecular level. 
Recombinant fragments of monoclonal antibodies targetin  selected human antigens are 
constructed to be used as potential diagnostic or immunotherapeutic agents, and as 
molecular tools for better structural and functional characterization of their antigens.  
 
 
Specific research aims:  
 
• Structural characterization of deoxyribonucleoside regulator from Bacillus 
subtilis, the binding of the ligand deoxyribose-5-phosphate, nd the effect of the 
ligand-induced structural changes on the function of the regulator.  
 
• Definition of the binding epitope of monoclonal antibody MEM-85 in the 
hyaluronate-binding domain of human CD44 receptor and structural 
characterization of the antibody-induced conformational changes in the antigen 
and their impact on CD44 function.  
 
 34 
7 Publications  
 
1. Crystallization of the effector-binding domain of repressor DeoR from Bacillus 
subtilis  
Pisackova, J., Prochazkova, K., Fabry, M. & Rezacova, P. (2013), Crystal Growth and 
Design. 13, 844-848.  
IF2013 = 4.558 
 
2. Structure of the effector-binding domain of deoxyribonucleoside regulator DeoR 
from Bacillus subtilis  
Skerlova, J., Fabry, M., Hubalek, M., Otwinowski, Z. & Rezacova, P. (2014), The FEBS 
Journal. 281, 4280-4292.  
IF2013/2014 = 3.986 
 
3. Optimization of the crystallizability of a single-chain antibody fragment*  
Skerlova, J., Kral, V., Fabry, M., Sedlacek, J., Veverka, V. & Rezacova, P. (2014), Acta 
Crystallographica Section F, Structural Biology and Crystallization Communications. 70, 
1701-1706.  
IF2013/2014 = 0.568 
 
4. Molecular mechanism for the action of the anti-CD44 monoclonal antibody MEM-
85  
Skerlova, J., Kral, V., Kachala, M., Fabry, M., Bumba, L., Svergun, D. I., Tosner, Z., 
Veverka V. & Rezacova, P. (2015), under consideration in Journal of Structural Biology.  
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7.1 Crystallization of the effector-binding domain of repressor DeoR 
from Bacillus subtilis  
 
Background  
Carbon catabolite repression in Bacillus subtilis, the model Gram-positive bacterium, 
has been intensively studied on cellular and molecular level. However, little investigation 
has been done on structural characterization of the proteins involved in the regulation of 
the expression of metabolic genes. Structural studies of these repressors would provide the 
needed insight into the carbon catabolite repression in Gram-positive bacteria as well as 
the general mechanisms of gene regulation. In this work, we focused on the preparation of 
crystals of the C-terminal effector-binding domain of the deoxyribonucleoside regulator, 
DeoR, suitable for X-ray diffraction analysis in orde  to gain structural information on the 
effector binding and the effector-induced conformational changes.  
 
Summary  
We prepared a recombinant C-terminal effector-binding domain of DeoR (C-DeoR) 
from Bacillus subtilis. Initial crystallization trials yielded thin needl-shaped crystals 
which could only be optimized to poorly-diffracting rod-shaped crystal clusters. In order to 
obtain high quality monocrystals suitable for X-ray diffraction experiments, we employed 
Thermofluor assay to screen for a buffer composition optimal for protein stability, 
homogeneity, and therefore, crystallizability. In this assay, C-DeoR exhibited the highest 
melting temperature in citrate buffer, which was identified as the optimal protein storage 
buffer. The subsequent crystallization screening experiments gave rise to new crystal forms 
for both the free and effector-bound C-DeoR, that were further optimized to large 
three-dimensional monocrystals. We collected three complete diffraction data sets for the 
free and effector-bound C-DeoR. The processed data can be used to solve the structures by 
molecular replacement using some of the available three-dimensional structures of 
homologous bacterial repressor proteins. Some of the key results of the publication are 





Figure 8: Optimization of the C-DeoR crystals using Thermofluor assay  
A: Needle-shaped C-DeoR crystals from the initial crystallization screening in the original protein storage 
buffer are shown. B: Three-dimensional C-DeoR crystals obtained from the crystallization optimization 
experiments in the optimized protein storage buffer ar  shown. C: Screening for the optimal protein storage 
buffer composition by Thermofluor assay is illustrated by a plot of the C-DeoR melting temperatures (Tm) in 
various buffers. The original Tris-based protein storage buffer is shown in black and the optimized protein 
storage buffer in blue.  
 
 
My contribution   
I prepared recombinant C-DeoR protein, performed protein storage buffer optimization 
by the Thermofluor assay, conducted both the screening and optimization crystallization 
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7.2 Structure of the effector-binding domain of deoxyribonucleoside 
regulator DeoR from Bacillus subtilis  
 
Background  
In this work, which followed the results of the previous publication “Crystallization of 
the effector-binding domain of repressor DeoR from Bacillus subtilis”, we aimed at 
a detailed structural characterization of the C-terminal effector-binding domain of 
deoxyribonucleoside regulator, DeoR, a repressor prtein taking part in the carbon 
catabolite repression in Bacillus subtilis. In particular, we were interested in the structural 
aspects of effector binding by DeoR. From the known three-dimensional structures of other 
metabolic regulators from Bacillus subtilis, we can say that although the effector-binding 
domains of the individual repressors represent commn conserved folds, the molecular 
mechanisms of the regulatory function of each repressor are quite unique. Therefore, 
a detailed study of the DeoR molecular mechanics would contribute to complex 
understanding of prokaryotic transcriptional regulation.  
 
Summary  
We determined crystal structures of the effector-binding domain of the 
deoxyribonucleoside regulator (C-DeoR) from Bacillus subtilis both in the free form and in 
the complex with the effector deoxyribose-5-phosphate. The effector-bound C-DeoR 
structure revealed a unique mode of effector binding through a reversible covalent 
Schiff-base double bond to a lysine residue in the eff ctor-binding site. This is the first 
case of a transcriptional factor that binds the effector molecule covalently. The 
physiological nature of this covalent effector binding mode was confirmed by mutational 
analysis combined with differential scanning fluorimetry (Thermofluor assay) and by mass 
spectrometry analysis of the formation of the Schiff-base complex in solution. Detailed 
structural analysis of the free and effector-bound C-DeoR structures, supported by the 
size-exclusion chromatography data, allowed us to propose a model for the DeoR function 
as a molecular switch. Some of the key results of the publication are summarized in 




Figure 9: C-DeoR crystal structure and a model of DeoR function 
A: Overall structure cartoon diagram with the topology description is shown for C-DeoR in complex with the 
effector deoxyribose-5-phosphate (shown in sticks). Double-Rossman-fold core (green) and peripheral 
subdomains (P1, P2, P3) are highlighted in colors. B: A detail of the effector molecule covalently bound to 
the effector-binding-site lysine residue is shown with the difference electron density map for the ligand 
contoured at 2.5 σ. C: Schematic representation of the tetrameric assembly of the full-length DeoR on the 
DNA operator site is shown in the high-affinity free state (left) and in the low-affinity effector-bound induced 
state (right).  
 
 
My contribution  
I participated in determination of crystal structure of the effector-bound C-DeoR, 
I determined the structure of free C-DeoR, refined both structure models and performed 
complete structure analysis. I purified the mutant d full-length C-DeoR proteins, 
performed the differential scanning fluorimetry (Thermofluor) assay and size-exclusion 
chromatography, prepared C-DeoR – effector adduct samples for mass spectrometry, and 
wrote the manuscript.  
 
 
Structure of the effector-binding domain of deoxyribonucleoside regulator DeoR from 
Bacillus subtilis. Skerlova, J., Fabry, M., Hubalek, M., Otwinowski, Z. & Rezacova, P. 

































Single-chain variable antibody fragments (scFvs) are engineered proteins of major 
therapeutic and diagnostic potential. Understanding the antigen-binding properties of the 
antibodies as well as employing various protein-engineering approaches including 
antibody humanization relies on the knowledge of antibody three-dimensional structure. 
Majority of scFv fragments tend to spontaneously oligomerize, which impairs their 
homogeneity, and therefore presents a major obstacle in rystallization. This work presents 
a new approach to scFv crystallizability optimization, demonstrated on a representative 
scFv fragment of anti-CD3 antibody MEM-57. The approach employs 
a Thermofluor-based assay to screen for optimal conditi s both for stability and for 
oligomeric homogeneity of the scFv fragment. In the optimized conditions, scFv MEM-57 
exhibited significantly improved ability to yield crystals.  
 
Summary  
We constructed a single-chain variable fragment (scFv) of anti-CD3 antibody 
MEM-57. Pre-crystallization biochemical and biophysical analysis of the purified protein 
using a combination of size-exclusion chromatography and dynamic light scattering 
revealed the presence of scFv dimer and higher oligomers and general heterogeneity of the 
sample, unfavorable for crystallization. Thermofluor assay was used to screen for the 
conditions optimal not only for protein stability, but also for protein sample oligomeric 
homogeneity, preferentially stabilizing scFv monomer. The beneficial effect of the 
optimized protein storage buffer was confirmed by the size-exclusion chromatography and 
dynamic light scattering data and finally by the results of crystallization screening trials. 
This approach may resolve the issue of unfavourable oligomerization of scFv fragments in 
general and result in scFv samples with improved crystallizability. The key results of the 




Figure 10: Optimization of crystallizability of scFv MEM-57 
A: A schematic of the scFv MEM-57 gene construct and protein product is shown. VH and VL are the 
variable domains of the heavy and light IgG chains, respectively; pelB is a leader sequence targeting 
recombinant protein to the periplasm, c-myc and His5 are immunodetection and purification tags, 
respectively. B: Thermofluor-based protein-unfolding curves for the original (black) and optimized (green) 
storage buffers are shown along with representative multiple-inflection curves (blue). C: A schematic of the 
crystallization screening plate containing the PEGs Suite (Qiagen) is shown. Conditions yielding crystals are 
highlighted in green. D: An example of crystals obtained using 100 mM HEPES pH 7.5, 25% (w/v) PEG 
3000 is shown.  
 
 
My contribution  
I expressed and purified recombinant scFv MEM-57, performed all the biochemical 
and biophysical experiments: size-exclusion chromatgr phy, Thermofluor assay, and 
dynamic light scattering. I performed the crystallizat on screening experiments, and wrote 
the manuscript.  
 
 
Optimization of the crystallizability of a single-chain antibody fragment. Skerlova, J., Kral, 
V., Fabry, M., Sedlacek, J., Veverka, V. & Rezacova, P. (2014), Acta Crystallographica 

















7.4 Molecular mechanism for the action of the anti-CD44 monoclonal 
antibody MEM-85  
 
Background  
Human hyaluronate receptor CD44 plays an important role in various physiological 
processes including cell adhesion and migration, such as hematopoiesis, lymphocyte 
homing, tissue healing, but also tumor metastasis. The transmembrane glycoprotein CD44 
binds hyaluronate through the extracellular hyaluronate-binding domain (HABD), which 
induces an allosteric conformational change, resulting in CD44 HABD shedding. Murine 
monoclonal antibody MEM-85 recognizes CD44 HABD and might be of therapeutic 
interest as it has been shown to inhibit growth of lung cancer cells in murine models. 
MEM-85 cross-blocks hyaluronate binding to CD44 and also induces CD44 shedding, 
similar to hyaluronate-induced CD44 shedding, by an unknown mechanism. The epitope 
recognized by MEM-85 has not been unambiguously ident fi d. Therefore, a detailed 
structural study of the MEM-85 – CD44 HABD interaction would shed light on the 
molecular mechanism of MEM-85 function.  
 
Summary  
We constructed a single-chain variable fragment (scFv) of murine antibody MEM-85 
against the hyaluronate-binding domain (HABD) of human CD44. Flow cytometry and 
fluorescence microscopy confirmed that scFv MEM-85 binds native CD44 on cell surface. 
Thermofluor assay revealed high thermal stability of the antibody fragment. We prepared 
recombinant 15N/13C-labeled CD44 HABD, which was able to bind hyaluronate, as shown 
by NMR. We analyzed the antigen binding of both scFv and IgG MEM-85 using surface 
plasmon resonance (SPR). Preparation of a stable homogeneous complex of scFv MEM-85 
and CD44 HABD allowed us to employ NMR and small-angle X-ray scattering (SAXS) 
analyses. We acquired a set of three-dimensional NMR spectra for the sequence-specific 
backbone resonance assignments for CD44 HABD. We used the minimal shift approach to 
assess the extent of the chemical shift perturbation upon scFv MEM-85 binding. By this 
approach, we identified the epitope, located in the C-terminal portion of CD44 HABD, 
which was corroborated with the results of a mutational analysis of the identified epitope 
residues combined with SPR measurements. Finally, we obtained a low-resolution ab initio 
SAXS structure of the complex together with a rigid body model of the complex using the 
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available high-resolution structures. The key results of the publication are summarized in 




Figure 11: Identification of MEM-85 binding epitope in CD44 HABD 
A: Two-dimensional 15N/1H HSQC spectra are shown for free 15N/13C-CD44 HABD (black) and 
15N/13C-CD44 HABD in complex with scFv MEM-85 (red). B: Histogram of minimal combined chemical 
shift versus the protein sequence is shown for 15N/13C-CD44 HABD. C: Significantly perturbed residues are 
mapped on the surface of free CD44 HABD. D: Significantly perturbed residues are mapped on the surface 
of hyaluronate-bound CD44 HABD. E: SAXS ab initio envelope (grey) is shown in superposition with the 
rigid body model of scFv MEM-85 (red) and CD44 HABD (green).  
 
 
My contribution  
I participated in the construction of the CD44 HABD expression vectors, prepared 
protein samples for all experiments, participated in the flow cytometry and fluorescence 
microscopy experiments, performed size-exclusion chromatography, dynamic light 
scattering, and Thermofluor assay. I performed the sequence-specific backbone NMR 
assignments and the chemical shift perturbation analysis by the minimal shift method. 
I prepared samples for SAXS measurements, participated in SAXS data analysis, and 
I wrote the manuscript.  
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Skerlova, J., Kral, V., Kachala, M., Fabry, M., Bumba, L., Svergun, D. I., Tosner, Z., 
































































Figure A.1: Binding of hyaluronate hexamer to CD44 HABD  
Two-dimensional 15N/1H HSQC spectra are shown for free 15N-CD44 HABD (black) and 




Figure A.2: The CD44 HABD – scFv MEM-85 complex is monodisperse.   
Mean particle size distribution determined by dynamic light scattering indicates 





Figure A.3: Rigid body model fit to SAXS data 
A:  Fit of the theoretical scattering of the rigid body model of the CD44 HABD – scFv 
MEM-85 complex to SAXS experimental data (black) is shown for epitope residues 160-
163 (red), where χ2 = 1.24, and for epitope residues 38-42 (green), where χ2 = 2.01. B: The 




Figure A.4: CD44 HABD and scFv MEM-85 SAXS model with flexible tail  
A:  The CORAL model of the complex of CD44 HABD (green; PDB code 2I83) (5) and 
scFv MEM-85 model (6) (red) is shown fitted into the SAXS ab initio envelope. The 
disordered C-terminal portion of CD44 HABD (residues 164-178) is modeled as a C-alpha 
trace (shown in bold). B: Fit of the theoretical scattering of the CORAL model of the 
CD44 HABD – scFv MEM-85 complex to the SAXS experimental data (black), where χ2 = 
1.29 is shown in gray.  
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8 Discussion  
 
8.1 Structural studies of deoxyribonucleoside regulator form Bacillus 
subtilis  
Structural data on several key transcriptional regulators from B. subtilis obtained so far 
indicate that although the effector-binding domains of the repressors represent conserved 
folds typical for individual protein families, each of them exhibits a unique mode of action 
determined by specific effector-induced structural changes and oligomerization pattern. 
Therefore, structural studies of several members of the B. subtilis families of 
transcriptional regulators are necessary for the full understanding of the distinct molecular 
mechanisms of carbon catabolite repression in Gram-positive bacteria and also gene 
regulation in general. In this part of the work, we focused on X-ray crystallographic 
analysis of the C-terminal effector-binding domain of deoxyribonucleoside regulator DeoR 
from B. subtilis.  
 
Crystals suitable for X-ray diffraction analysis were obtained by elaborate optimization 
of crystallization conditions. First crystallization trials with recombinant C-DeoR 
expressed in E.coli yielded thin needle-shaped crystals in 8 out of 96 screened 
crystallization conditions. Despite the extensive effort to optimize the initial crystallization 
conditions, only rod-shaped crystals of poor diffraction quality were obtained. Therefore, 
we employed the Thermofluor-based optimization of the protein storage buffer to achieve 
maximal protein stability. This assay revealed protein thermal stabilization by phosphate 
ions, but these buffers were not taken into account for he crystallization, as binding of 
phosphate was shown before for other bacterial transcription factors [15, 16]. The 
Thermofluor assay also identified a combined stabilizing effect of citrate buffer and the pH 
value of around 7.5. A combination of these two conditions was used in the optimized 
protein storage buffer (based on tri-sodium citrate pH 7.0) for new crystallization screening 
trials both in the presence and absence of the effector (dexyribose-5-phospate). These trials 
yielded crystals in 8 out of 96 conditions for the effector-bound protein, which were 
different from those for the original protein storage buffer. The free C-DeoR protein in the 
optimized storage buffer yielded crystals in 31 outf 96 screened conditions. Most of the 
crystals were again represented by needle or plate c usters, but new crystal forms were 
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obtained for both the free and effector-bound C-DeoR, which were three-dimensional 
monocrystals. These results proved that the Thermofluor-based buffer optimization 
technique generally used in order to improve protein stability, and therefore its 
crystallizability can be used to obtain new, better diffracting crystal forms of otherwise 
well crystallizing protein.  
The new crystal forms of C-DeoR were easily optimized to large well-diffracting 
monocrystals suitable for X-ray diffraction experiments. Three complete data sets were 
acquired for the free C-DeoR (space group P32 or P31, resolution 1.90 Å) and for the 
effector-bound C-DeoR (space group C2221, resolution 1.60 Å, and space group P2221, 
resolution 1.65 Å). The sequence similarity of C-DeoR with the homologous 
transcriptional regulators with known three-dimensio al structures suggested that C-DeoR 
crystal structures can be solved using the molecular replacement method. The putative 
sugar-binding transcriptional regulator from Arthrobacter aurescens (PDB code 3NZE) 
shows 52% sequence similarity and 30% sequence identity with 259 DeoR residues, the 
probable sorbitol operon regulator from Shigella flexneri (PDB code 3EFB) shows 49% 
sequence similarity and 31% sequence identity with 265 DeoR residues, and the sorbitol 
operon regulator SorC from Klebsiella pneumoniae (PDB code 2W48) shows 50% 
sequence similarity and 30% sequence identity for 246 DeoR residues [152].  
 
The next step in this project was the determination of the C-DeoR structures. The 
structure of effector-bound C-DeoR was determined at resolution of 1.60 Å by molecular 
replacement using the homologous putative sugar-binding transcriptional regulator from 
Arthrobacter aurescens (PDB code 3NZE) as the search model. The refined eff ctor-bound 
C-DeoR structure was then used as a molecular replac ment search model for the 
determination of the unliganded C-DeoR structure using a dataset acquired at 1.80 Å 
resolution.  
The C-DeoR structure is composed of a central double-Rossmann-fold core, typical for 
dinucleotide-binding proteins [153], which is supplemented on both sides with a total of 
5 α-helices, resulting in an overall α/β fold of the core subdomain. Additionally, the 
C-DeoR is equipped with three, mostly helical peripheral subdomains, which take part in 
effector binding and repressor oligomerization. The eff ctor-binding site, formed by the 
interface of the core subdomain and two peripheral subdomains, binds the effector 
molecule deoxyribonuceloside-5-phosphate in a linear form, through a reversible 
Schiff-base double bond with residue Lys141 located in one of the peripheral subdomains. 
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The phosphate moiety of the effector molecule interracts with the N-terminal end of one of 
the Rossmann fold α-helices, an interaction motif typical for dinucleotide-binding 
Rossmann-fold proteins [153-155].  
C-DeoR shows structural homology [156] to numerous prokaryotic transcriptional 
regulators from the SorC family. C-DeoR is also homologous to central glycolytic genes 
regulator CggR from B. subtilis (PDB code 3BXF [15]), which exhibits a very similar 
organization of the effector-binding site and also binds its ligands in a very similar pose to 
that of C-DeoR. Moreover, C-DeoR structure is homolog us to many enzymes involved in 
prokaryotic sugar metabolism, such as 6-phosphoglucnolactonase, 
glucose-6-phosphate-1-dehydrogenase and glucosamine-6-phosphate deaminase. This 
indicates that one common protein fold can be adapted to performing various enzymatic 
and regulatory functions. One such enzyme, ribose-5-phosphate isomerase A from 
Burkholderia thailandensis (PDB code 3UW1 [157]) also binds its substrate 
ribose-5-phospate in a linear form in an orientation very similar to that of 
deoxyribose-5-phosphate in C-DeoR. The Schiff base, however, cannot be formed here, as 
ribose-5-phosphate isomerase A contains a serine residue instead of the lysine in the active 
site. The Schiff-base adduct of deoxyribose-5-phospate has been observed also in the 
structure of deoxyribose-5-phosphate aldolase form E. coli, where it represents a reaction 
intermediate (PDB code 1JCJ [158]). The length of the imine bond in the aldolase structure 
is 1.29 Å and the Nζ-C-C angle is 125°, which are identical values to th se in the C-DeoR 
structure.  
Our effector-bound C-DeoR structure is the only crystal structure of a transcriptional 
factor capturing a covalently bound effector molecu. The physiological nature of the 
covalent bond was confirmed by the mass spectrometry analysis of the Schiff-base 
products formed in solution under physiological concentrations of 
deoxyribose-5-phosphate [159]. The mass to charge ratio difference between the two 
detected MALDI-TOF peaks corresponding to free C-DeoR and the C-DeoR Schiff-base 
adduct was equal to the mass of the cyanoborohydride-re uced deoxyribose-5-phosphate 
adduct, 3,4-dihydroxy-5-(phosphonooxy)pentyl residue. Moreover, the abundance of the 
higher molecular mass peak increased with the incubation time. Mutational analysis 
combined with the Thermofluor-based differential scanning fluorimetry assay [160-162] 
confirmed the key role of Lys141 in effector binding. The titration of Lys141-mutant 
proteins K141N, K141Q, K141R, or K141A, respectively, by deoxyribose-5-phosphate 
showed only small increase in the thermal stability of the mutant proteins when compared 
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to the thermal stabilization of the wild-type C-DeoR. This suggests that Lys141 is essential 
for proper effector binding.  
The superposition of the Cα atoms of the free and effector-bound C-DeoR structu es 
identified the location and the extent of the effector-induced structural changes. Major 
changes occur around the effector-binding site and in the adjacent peripheral subdomains, 
and are in some extent similar to those observed in CggR [15]. The structural changes in 
the parts of peripheral subdomains that are involved in the dimeric interface might affect 
the protein’s oligomeric state as they disrupt the dimer interface and reduce the interface 
area from 1367.3 Å2 formed by 40 interacting residues in the free C-DeoR dimer to 
841.3 Å2 formed by 25 interacting residues in the effector-bund C-DeoR dimer. The 
interface is formed by a peripheral subdomain of C-DeoR and also in part by a portion of 
the double-Rossmann-fold core, in a manner similar to dimers of other members of the 
SorC family, such as CggR [15], putative sugar-binding transcriptional regulator from A. 
aurescens (PDB code 3NZE), and SorC [152]. The size-exclusion and dynamic light 
scattering experiments with the C-DeoR and full-length DeoR both in the presence and 
absence of deoxyribose-5-phosphate have shown that C-DeoR and full-length DeoR persist 
in the dimeric and tetrameric forms, respectively, even upon effector-binding. This 
suggests the presence of two dimerization interfaces in the full-length DeoR: one in the 
effector-binding domain, and the second in the DNA-binding domain. We suggested 
a model for the regulation of DeoR function: the tigh  tetramer of DeoR binds to 
a palindromic operator sequence [20, 25], but in the presence of deoxyribose-5-phosphate, 
the effector-induced structural change in the effector-binding domains disrupts the 
dimerization interfaces in both the effector- and allosterically also in the DNA-binding 
domains and the less tight tetramer can be easily displaced from the operator by RNA 
polymerase. The exact structural mechanism, however, still remains to be unraveled by the 
determination of the full-length DeoR structures, ideally in complex with the operator 
DNA.  
 
8.2 Epitope mapping for the anti-CD44 monoclonal antibody MEM-85 
Monoclonal antibodies are molecules with immense thrapeutic and diagnostic 
potential. The same applies to their single-chain variable fragments (scFv), the smallest 
antibody fragments that retain the antigen-binding properties while having a relatively 
small size which makes them excellent molecular biology tools for the characterization of 
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antigen binding. The only drawback that might compromise their use for some applications 
is their spontaneous oligomerization. This issue might be, however, resolved by some 
optimization approaches, as described in the first part of this section on a model case of the 
scFv fragment of the anti-CD3 antibody MEM-57. The s cond part of this project is 
focused on antibody MEM-85, which is one of the therap utically applicable antibodies 
targeted against the CD44 antigen. CD44 has been recently identified to be involved in 
many aspects of cancer and in the last few years, novel CD44-targeted immunotherapeutic 
approaches keep emerging and seem to be very promising. Antibody MEM-85 has been 
widely used as a molecular biology tool, but its epitope has not been unambiguously 
described so far, which was the goal of this project.  
 
We constructed an scFv fragment of antibody MEM-57 for recombinant expression in 
E. coli. The variable domains of the heavy and light chains were connected via 
a (Gly4Ser)4 linker sequence. A longer version of the conventional (Gly4Ser)3 linker [163] 
was used here, which should reduce the spontaneous oligomerization of scFv fragments, 
observed typically for shorter linker sequences [164- 8]. Size-exclusion analysis of the 
purified scFv revealed equilibrium between scFv monomeric and oligomeric forms, where 
the monomer represented only 65% of the total scFv. This equilibrium re-establish even 
after the separation of scFv monomers and dimers using ion-exchange chromatography. 
This oligomerization reduced the effective protein yield, but, more importantly, presented 
a disadvantage in the use of the scFv fragments for experiments that require high protein 
homogeneity.  
The oligomeric equilibrium is not only a function of the linker sequence length, but it 
also depends on other aspects such as protein concentration and the pH and ionic strength 
of the protein storage buffer [169]. In order to resolve the oligomerization issue, we 
employed the Thermofluor assay to screen for conditions that would preferentially stabilize 
scFv monomers, and thus reduce the oligomeric heterogeneity of the protein sample. The 
Thermofluor-based thermal denaturation curve for a homogeneous protein has a typical 
shape containing only one inflection point which indicates the melting temperature point 
(Tm). Therefore, multi-inflection curves were excluded from the Tm analysis and the buffer 
which provided scFv denaturation curve with one inflection point and the highest Tm was 
selected as the optimal protein storage buffer for further experiments. Size-exclusion 
analysis and dynamic light scattering confirmed scFv homogeneity in the optimized 
protein storage buffer (the monomer represented 88%of the total protein). Our results 
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suggested that Thermofluor assay nowadays routinely used for protein stability 
optimization [162, 170] can be of help also in the efforts to resolve the undesirable 
oligomerization issue of scFv fragments in general, including for example the anti-CD44 
scFv MEM-85 studied in the following part of this project.  
 
For the anti-CD44 antibody MEM-85, we have constructed a recombinant scFv 
fragment in which the variable domains of the heavy nd light chains were connected via 
a (Gly4Ser)4 linker sequence, similarly to MEM-57. The recombinant scFv MEM-85 was 
able to bind native CD44 on the surface of CD44-positive cells as confirmed by flow 
cytometry and fluorescence microscopy, and it also bound recombinant 
hyaluronate-binding domain (HABD) of CD44 as confirmed by surface plasmon resonance 
(SPR). SPR analysis of the binding affinities of scFv MEM-85 and IgG MEM-85 revealed 
lower binding affinity of scFv MEM-85 (KD = 430 ± 60 nM) when compared to IgG 
MEM-85 (KD = 4.0 ± 1.7 nM), which is in concordance with a generally observed trend 
[171]. Preparation of a highly stable and homogeneous scFv sample (employing the 
Thermofluor assay optimization) and a sample of the CD44 HABD – scFv MEM-85 
complex (employing size-exclusion chromatography and dynamic light scattering) was 
necessary for the further NMR and SAXS experiments aimed at the characterization of 
MEM-85 epitope and the antibody-induced conformational changes in CD44 HABD. The 
MEM-85 epitope residues in CD44 HABD were identified by using the chemical shift 
perturbation method on the backbone NMR signals, acquired in the sets of 
three-dimensional experiments performed on the free 15N/13C-labeled CD44 HABD and on 
the complex of the 15N/13C-labeled CD44 HABD with scFv MEM-85. Locating the 
significantly perturbed residues on the surfaces of the available three-dimensional 
structures of CD44 HABD (unliganded O-conformation [62] and the hyaluronate-bound 
PD-conformation [64]) revealed that the epitope is located in the C-terminal part of the 
HABD extension lobe, clustered around the most perturbed residues 160-163. The role of 
these residues in antibody binding was confirmed by mutational analysis combined with 
SPR: mutations of residues 160, 161, and 163 to alanines significantly reduced MEM-85 
affinity towards CD44 HABD. These data were also corroborated with the rigid body 
model of the CD44 HABD – scFv MEM-85 complex, that was created based on the 
low-resolution structure of the complex obtained by small-angle X-ray scattering (SAXS). 
The rigid body model with the epitope defined as residues 160-163 provided a perfect fit to 
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the experimental data, unlike the epitope defined as residues 38-42, based on the previous 
mutational experiments performed by Bajorath et al. [33].  
The major conformational changes, that occur in the C-t rminus of CD44 HABD upon 
hyaluronate binding [64, 70] provide enhanced flexibility to the unstructured HABD tail 
and induce CD44 proteolytic shedding [64]. The key r sidue for this rearrangement is 
Tyr161 [70], which is also the residue exhibiting the highest normalized combined 
chemical shift in our NMR experiments. This suggests that the binding of MEM-85 
triggers a similar conformational change in HABD from the O- to the PD-conformation, 
which is also in agreement with our observation of sharpening of the NMR signals for the 
very C-terminal HABD residues in the antibody-bound state. Moreover, MEM-85 has also 
been shown to induce CD44 shedding similar to that induced by hyaluronate [151].  
Taken together, our results propose that MEM-85 recognizes an epitope located in the 
C-terminal part of CD44 HABD, including residues 160-163, and that the antibody binding 
induces conformational changes in the C-terminal region by a direct contact with residues 
around Tyr161. MEM-85 competes with hyaluronate for binding to CD44 HABD [33, 
150]. This could be explained by our finding that some of the residues that exhibit 
moderate antibody-induced chemical shift perturbations (including residues 38-42) are 
located in the vicinity of the hyaluronate-binding groove. These perturbations are too small 
to be caused by a direct binding of the antibody [172, 173] but rather suggest a secondary 
allosteric rearrangement triggered by antibody-induced conformational change in the 
C-terminal portion of HABD. This conformational change may be transmitted through 
residues 38-42 that are clustered in a linear patch reaching from residue Tyr161 towards 
the hyaluronate-binding groove. Therefore, MEM-85 does not directly compete with 






This work combines principal techniques that are usd to study protein-protein and 
protein-ligand interactions and the changes in protein conformation. X-ray crystallographic 
analysis was used to study the structure of deoxyribonucleoside regulator DeoR from 
Bacillus subtilis to understand the binding of an effector molecule. NMR-based mapping 
of the interaction interface was used to identify the location of the antigen-binding epitope 
of monoclonal antibody MEM-85 in the hyaluronate-binding domain of human CD44.  
 
The first part of this work describes an important contribution to the field of bacterial 
transcription regulation. We have crystallized the C-terminal effector-binding domain of 
deoxyribonucleoside regulator DeoR from Bacillus subtilis (C-DeoR). The new crystal 
form of C-DeoR, optimal for X-ray diffraction experiments, was obtained based on an 
extensive biophysical characterization of the C-DeoR protein together with protein buffer 
optimization using Thermofluor assay. The crystal sructure of DeoR in complex with the 
effector molecule deoxyribose-5-phosphate revealed that DeoR binds the effector molecule 
deoxyribose-5-phosphate covalently via a Schiff-base double bond with a lysine residue in 
the effector-binding site. The formation of the Schiff-base adduct was also observed in 
solution at low effector concentrations and the keyrole of the effector-binding-site lysine 
residue was confirmed by mutational analysis. These findings make DeoR the first case of 
transcriptional regulator that binds its small-molecular ligand through a reversible covalent 
bond. Structural analysis of both C-DeoR in the fre form and in complex with the effector 
revealed effector-induced structural changes disturbing the dimeric interface in C-DeoR. 
These structural data allowed us to create a model describing the molecular mechanism of 
the DeoR function as a molecular switch.  
 
In the second part of this work, we have constructed a recombinant single-chain 
variable fragment (scFv) of monoclonal antibody MEM-85 targeted against CD44, the 
human cell receptor for hyaluronate, which is involved in cancer. Antibody MEM-85 is of 
therapeutic interest and needed to be characterized in terms of the antigen-binding epitope 
location and the effects on CD44 structure and functio . The scFv fragment is a suitable 
small-size molecular tool retaining the antigen-binding function and simplifying the whole 
antibody molecule. The highly homogeneous and stable sample of recombinant scFv 
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MEM-85 necessary for further experiments was prepared based on a general strategy of 
optimization of the biophysical properties of scFv fragments, developed also in the 
framework of this project. NMR-based epitope mapping was employed to unambiguously 
locate the epitope of MEM-85 in the C-terminal region of the hyaluronate-binding domain 
(HABD) of CD44. Moreover, the antibody binding induced allosteric conformational 
changes which lead to an increased disorder in the C-terminal tail of HABD. The character 
of this conformational rearrangement was similar to that induced by hyaluronate-binding. 
These important data shed light on the previous observations that MEM-85 cross-blocks 
hyaluronate binding to CD44 and also induces CD44 shedding. MEM-85 does not do so by 
a direct physical competition for the hyaluronate-binding site, but rather allosterically, by 
binding to a distant epitope located close to the membrane-proximal C-terminus of HABD. 
Small-angle X-ray scattering and mutational experimnts combined with surface plasmon 
resonance allowed us to create a rigid body model for the complex of scFv MEM-85 with 
CD44 HABD that further corroborates the proposed MEM-85 mode of action.  
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